Hematologic Malignancy
Acute Biphenotypic Leukemia
CI-CAN-00007129Explore in graph →
Hematologic14 active trials
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00007129Explore in graph →
Clinical trials
41 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (9)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05589896 | A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Transplantation for Patients With Hematologic Malignancies | active not recruiting | Phase 1 / Phase 2 | 12 | Ossium Health, Inc.INDUSTRY | 1 | Sep 10, 2026 | clinicaltrials |
| NCT02159495 | Genetically Modified T-cell Immunotherapy in Treating Patients With Relapsed/Refractory Acute Myeloid Leukemia and Persistent/Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm | active not recruiting | Phase 1 | 31 | City of Hope Medical CenterOTHER |
| 1 |
| Aug 26, 2026 |
| clinicaltrials |
| NCT04047641 | Cladribine, Idarubicin, Cytarabine, and Quizartinib in Treating Patients With Newly Diagnosed, Relapsed, or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome | recruiting | Phase 1 / Phase 2 | 80 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT03326921 | HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant | recruiting | Phase 1 | 24 | Fred Hutchinson Cancer CenterOTHER | 1 | May 18, 2026 | clinicaltrials |
| NCT04797767 | Venetoclax and CLAG-M for the Treatment of Acute Myeloid Leukemia and High-Grade Myeloid Neoplasms | recruiting | Phase 1 / Phase 2 | 62 | University of WashingtonOTHER | 1 | Apr 17, 2026 | clinicaltrials |
| NCT05170828 | Cryopreserved MMUD BM With PTCy for Hematologic Malignancies | withdrawn | Phase 1 | 0 | Ossium Health, Inc.INDUSTRY | 0 | Feb 24, 2026 | clinicaltrials |
| NCT04874194 | Omacetaxine and Venetoclax for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Harboring Mutant RUNX1 | terminated | Phase 1 / Phase 2 | 24 | M.D. Anderson Cancer CenterOTHER | 1 | Nov 3, 2025 | clinicaltrials |
| NCT04526795 | Fludarabine, Cytarabine, and Pegcrisantaspase for the Treament of Relapsed or Refractory Leukemia | terminated | Phase 1 | 19 | M.D. Anderson Cancer CenterOTHER | 1 | Dec 12, 2024 | clinicaltrials |
| NCT02728050 | Filgrastim, Cladribine, Cytarabine, and Mitoxantrone With Sorafenib in Treating Patients With Newly-Diagnosed, Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome | completed | Phase 1 / Phase 2 | 84 | University of WashingtonOTHER | 1 | Jul 5, 2023 | clinicaltrials |
| NCT02529813 | CD19-Specific T-cells in Treating Patients With Advanced Lymphoid Malignancies | completed | Phase 1 | 26 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 30, 2022 | clinicaltrials |
| NCT05066958 | Ex-vivo Primed Memory Donor Lymphocyte Infusion to Boost Anti-viral Immunity After T-cell Depleted HSCT | unknown | Phase 1 / Phase 2 | 20 | Federal Research Institute of Pediatric Hematology, Oncology and ImmunologyOTHER | 1 | Oct 4, 2021 | clinicaltrials |
| NCT03807063 | Rivogenlecleucel Donor Lymphocyte Immunotherapy in Treating Patients With Recurrent Blood Cancers After Stem Cell Transplant | withdrawn | Phase 1 | 0 | Fred Hutchinson Cancer CenterOTHER | 1 | Aug 14, 2020 | clinicaltrials |
| NCT01619761 | NK Cells in Cord Blood Transplantation | unknown | Phase 1 | 13 | M.D. Anderson Cancer CenterOTHER | 1 | Feb 11, 2020 | clinicaltrials |
| NCT02044796 | Filgrastim, Cladribine, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Newly Diagnosed or Relapsed/Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes | completed | Phase 1 / Phase 2 | 199 | Fred Hutchinson Cancer CenterOTHER | 1 | Jan 10, 2020 | clinicaltrials |
Data updated 20 days agoSource updated Sep 10, 2026source: clinicaltrials